Leronlimab apparently doesn't work as well as management would like the FDA, shareholders, etc., to believe. Particularly concerning is that the mab didn't perform well in the severe population in CD12. Maybe if four doses had been administered, it would have been a different story. But until this situation is rectified and until LL performs better in any clinical trial, I don't see the investment thesis for CYDY.
Market Data 
Markets 
AI
